Abstract:
Small cell lung cancer (SCLC) is a subtype of lung cancer with poor prognosis. Although it is sensitive to radiotherapy and chemotherapy in the early stages, most patients die from tumor recurrence and metastasis in a short period of time. Lots of studies are aimed at investigating prognostic biomarkers and optimize the efficacy of drugs through individualization in patients with SCLC. There are many reports on the association between tumor-infiltrating lymphocytes (TILs) and prognosis of the tumor (including non-SCLC, breast cancer, colorectal cancer, and melanoma) and efficacy of immunotherapy. We review the role of TILs in the prognosis of SCLC and efficacy of drugs.